243 related articles for article (PubMed ID: 17515399)
1. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma.
Qian J; Xie J; Hong S; Yang J; Zhang L; Han X; Wang M; Zhan F; Shaughnessy JD; Epstein J; Kwak LW; Yi Q
Blood; 2007 Sep; 110(5):1587-94. PubMed ID: 17515399
[TBL] [Abstract][Full Text] [Related]
2. A novel multi-epitope vaccine from MMSA-1 and DKK1 for multiple myeloma immunotherapy.
Lu C; Meng S; Jin Y; Zhang W; Li Z; Wang F; Wang-Johanning F; Wei Y; Liu H; Tu H; Su D; He A; Cao X; Zhou F
Br J Haematol; 2017 Aug; 178(3):413-426. PubMed ID: 28508448
[TBL] [Abstract][Full Text] [Related]
3. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.
Qian J; Wang S; Yang J; Xie J; Lin P; Freeman ME; Yi Q
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8808-15. PubMed ID: 16361569
[TBL] [Abstract][Full Text] [Related]
4. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
[TBL] [Abstract][Full Text] [Related]
5. Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma.
Qian J; Zheng Y; Zheng C; Wang L; Qin H; Hong S; Li H; Lu Y; He J; Yang J; Neelapu S; Kwak LW; Hou J; Yi Q
Blood; 2012 Jan; 119(1):161-9. PubMed ID: 22049519
[TBL] [Abstract][Full Text] [Related]
6. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O
Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595
[TBL] [Abstract][Full Text] [Related]
7. Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma.
Li R; Zheng C; Wang Q; Bi E; Yang M; Hou J; Fu W; Yi Q; Qian J
Haematologica; 2021 Mar; 106(3):838-846. PubMed ID: 32079700
[TBL] [Abstract][Full Text] [Related]
8. Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders.
Bae J; Smith R; Daley J; Mimura N; Tai YT; Anderson KC; Munshi NC
Clin Cancer Res; 2012 Sep; 18(17):4850-60. PubMed ID: 22753586
[TBL] [Abstract][Full Text] [Related]
9. Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma.
Jalili A; Ozaki S; Hara T; Shibata H; Hashimoto T; Abe M; Nishioka Y; Matsumoto T
Blood; 2005 Nov; 106(10):3538-45. PubMed ID: 16037388
[TBL] [Abstract][Full Text] [Related]
10. Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma.
Anderson LD; Cook DR; Yamamoto TN; Berger C; Maloney DG; Riddell SR
Cancer Immunol Immunother; 2011 Jul; 60(7):985-97. PubMed ID: 21461886
[TBL] [Abstract][Full Text] [Related]
11.
Khalaf WS; Garg M; Mohamed YS; Stover CM; Browning MJ
Front Immunol; 2019; 10():1792. PubMed ID: 31428094
[TBL] [Abstract][Full Text] [Related]
12. Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myeloma.
Belle S; Han F; Condomines M; Christensen O; Witzens-Harig M; Kasper B; Kleist C; Terness P; Moos M; Cremer F; Hose D; Ho AD; Goldschmidt H; Klein B; Hundemer M
Eur J Haematol; 2008 Jul; 81(1):26-35. PubMed ID: 18363871
[TBL] [Abstract][Full Text] [Related]
13. Identification of HLA-A*0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies.
Siegel S; Wagner A; Friedrichs B; Wendeler A; Wendel L; Kabelitz D; Steinmann J; Barsoum A; Coggin J; Rohrer J; Dreger P; Schmitz N; Zeis M
J Immunol; 2006 Jun; 176(11):6935-44. PubMed ID: 16709854
[TBL] [Abstract][Full Text] [Related]
14. Dominant responses with conservation of T-cell receptor usage in the CD8+ T-cell recognition of a cancer testis antigen peptide presented through HLA-Cw7 in patients with multiple myeloma.
Goodyear OC; Pearce H; Pratt G; Moss P
Cancer Immunol Immunother; 2011 Dec; 60(12):1751-61. PubMed ID: 21785964
[TBL] [Abstract][Full Text] [Related]
15. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
Hong S; Li H; Qian J; Yang J; Lu Y; Yi Q
Clin Exp Immunol; 2012 Nov; 170(2):167-77. PubMed ID: 23039887
[TBL] [Abstract][Full Text] [Related]
16. Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma.
Li R; Qian J; Zhang W; Fu W; Du J; Jiang H; Zhang H; Zhang C; Xi H; Yi Q; Hou J
Br J Haematol; 2014 Sep; 166(5):690-701. PubMed ID: 24824351
[TBL] [Abstract][Full Text] [Related]
17. MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes.
Mayr C; Bund D; Schlee M; Bamberger M; Kofler DM; Hallek M; Wendtner CM
Exp Hematol; 2006 Jan; 34(1):44-53. PubMed ID: 16413390
[TBL] [Abstract][Full Text] [Related]
18. A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma.
Bae J; Song W; Smith R; Daley J; Tai YT; Anderson KC; Munshi NC
Br J Haematol; 2012 Jun; 157(6):687-701. PubMed ID: 22533610
[TBL] [Abstract][Full Text] [Related]
19. Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis.
Schmidt SM; Schag K; Müller MR; Weinschenk T; Appel S; Schoor O; Weck MM; Grünebach F; Kanz L; Stevanovic S; Rammensee HG; Brossart P
Cancer Res; 2004 Feb; 64(3):1164-70. PubMed ID: 14871853
[TBL] [Abstract][Full Text] [Related]
20. Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination.
Kather A; Ferrara A; Nonn M; Schinz M; Nieland J; Schneider A; Dürst M; Kaufmann AM
Int J Cancer; 2003 Apr; 104(3):345-53. PubMed ID: 12569558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]